Our specialist medical device team work with diverse global companies within the industry to sustain growth, exploit current and future innovations, and secure their business's success. Our clients are multinational corporations and start-ups within the medical devices industry from companies within medical devices or in vitro diagnostic medical devices.
With sector-specific expertise grounded in scientific intelligence and technological know-how, clients value our knowledge of the regulatory frameworks shaping clients' strategic options, the technology being deployed, and our ability to execute complex legal solutions across multi-jurisdictions.
We ensure that our clients operate within the boundaries of medical regulations, data privacy, competition/anti-trust, procurement, pricing and reimbursement, advertising and promotion, and anti-bribery compliance/fraud and abuse laws.
We are pivotal in leveraging growth through strategic alliances, fundraisings, IP and compliant data privacy and security activities, and are relied on to resolve both offensive and defensive cross-jurisdiction patent litigation.
With in-depth sector expertise, we also actively engage with the wider medical devices industry through our connections with esteemed industry bodies and as leading voices in industry publications and wider expert webinar/seminar series.
Die börsennotierte Eckert & Ziegler Strahlen- und Medizintechnik AG, einer der weltweit größten Anbieter von isotopentechnischen Komponenten für Strahlentherapie und Nuklearmedizin mit Sitz in Berlin, hat die ebenfalls börsennotierte belgische Eckert & Ziegler BEBIG SA übernommen. Die internationale Wirtschaftskanzlei Taylor Wessing hat die Eckert & Ziegler Strahlen- und Medizintechnik AG hinsichtlich aller Aspekte der grenzüberschreitenden Verschmelzung rechtlich beraten. Die Transaktion dürfte die erste erfolgreiche Umsetzung einer grenzüberschreitenden Verschmelzung zweier börsennotierter Gesellschaften nach Deutschland auf der Grundlage der europäisch harmonisierten Vorgaben der EU-Gesellschaftsrichtlinie (EU) 2017/1132 sein.
Press release
Aktuelle News & Insights
Update: AI-Enabled Medical Devices and IVDs Confirmed as “High-Risk”
Digital Omnibus Update. More time (up to August 2028) yet confirming that AI-enabled medical devices and IVDs stay subject to the AI Act.
von Irina Rebin
4 von 9 Insights
CJEU on distributor's verification obligations under MDR
Medical device (and IVD) distributors. CJEU confirms that distributors need not repeat the manufacturer’s classification or conformity assessment, but must perform a “consistency check” for obvious inconsistencies.
von Irina Rebin
1 von 9 Insights
Grundsatzentscheidung des EuGH zu den Pflichten von Medizinprodukte-Händlern
von Dr. Daniel Tietjen und Daniel Dietrich
KI in Medizinprodukten - Orientierung im regulatorischen Doppelregime
EuGH-Generalanwalt zu den Händlerpflichten bei Medizinprodukten
von Dr. Daniel Tietjen und Daniel Dietrich